A Phase 2 interventional study of Ghrelin (OXE-103) and Placebo in Concussion, Brain and Traumatic Brain Injury, sponsored by Michael Rippee. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-05-21.
Sponsored by Michael Rippee · Phase 2, Interventional, and Treatment
Concussions are the leading form of mild traumatic brain injury. Management of concussions and mild traumatic brain injury is a high priority medical focus, social concern, and research topic. Currently, there are no FDA approved treatments for acute concussion. The current standard of care is rest followed by gradual return to normal activity. The purpose of this study is to show improvement in the way patients feel or function after a concussion.
OXE-103 is a protein hormone produced in the laboratory which identical to the hormone ghrelin that is secreted by the stomach. This study will investigate the use of this hormone as treatment for symptoms of acute concussion. The goal of this study is to show improvement in the way study participants feel or function after concussion.
An OXE-103 (ghrelin) agonist is already FDA approved for another condition, but not for concussion. For concussion, it is considered investigational.
This study will examine, if ghrelin is taken every day for two weeks, if the brain will heal faster and help improve or resolve symptoms. The study will also include a placebo arm and a non-treatment group (for those who wish to participate but do not want to receive any treatment). The OXE-103 and placebo will be self-administered through injections using needles.
All consenting participants will be screened for eligibility.
The study does not include randomization and all enrolling subjects will be offered treatment with OXE-103. Enrolling subjects will also have the option to choose participation in a non-treatment control group if they do not want treatment.
Consenting participants must be willing to commit to the following:
Total participation will last about 7 weeks, which includes screening, 14 days of taking the study drug, and 4 weeks of follow-up. Participation for the non-treatment group will last the same amount of time.
2,113 studies on the registry are indexed under Brain Injuries; 385 are open to participants now.
This study's enrollment of 23 is below the median of 48 across 1,331 interventional studies indexed under Brain Injuries.
Browse Brain Injuries studies →This is the only study on the registry with Michael Rippee as lead sponsor.
Counted across the registry records on this site, refreshed daily.
INCLUSION AND EXCLUSION:
Subjects must be consented within 28 days post injury.
Subjects will have a symptom severity score of at least 20 at the time of randomization in order to reduce the expected degree (number and severity) of spontaneous symptom resolution prior to study completion.
Subjects with pre-existing neurologic conditions other than mTBI (including cognitive dysfunction) will be excluded.
Subjects receiving, or planning to receive, a continuous ketamine infusion while enrolled in study will be excluded.
Subjects with these known endocrinological abnormalities at baseline will be excluded from study: diabetes mellitus, excess or deficiency of growth hormone, cortisol, or prolactin. Exclusion from study for any other endocrinological abnormalities or diagnoses existing at baseline are ultimately up to the discretion of the study physician.
Significant abnormalities in serum creatinine (>2.5 mg/dL), or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal, or bilirubin (>2.5 mg/dL) will exclude subjects from participation.
Subjects with any abnormal findings noted on imaging, such as hemorrhage, will be excluded from the study. Subjects who meet criteria for moderate or severe TBI will also be excluded.
Subjects who are known to be pregnant will be excluded. Subjects who do not agree to double-barrier contraception or abstinence (for female subjects of child-bearing potential or male subjects who are sexually active with a female of child-bearing potential) until the day following last dose (total of at least 5 half-lives) will be excluded.
Subjects receiving other concomitant medications, physical therapy, or other treatments related to their current mTBI will be eligible if they meet the inclusion criteria.
Subjects (or household members) who are not able to inject themselves or the subject will be excluded.
Subjects are not allowed to be concurrently enrolled in another therapeutic intervention clinical trial while participating in this study. Any subjects currently enrolled in such a separate therapeutic intervention clinical trial, for any condition, will be excluded from participating in this study. For clarification, this does not include observational clinical trials or registries.
Ultimately study subject participation will be at the discretion of the study physician.
Placebo (40ug/kg) will be self-administered twice daily for 14 days. ONLY THE PART B (ACUTE) SUBJECTS WILL BE RANDOMIZED AND MAY RECEIVE PLACEBO.
Drug: Placebo
OXE-103 (40ug/kg) will be self-administered twice daily for 14 days. PART A (POST-ACUTE) SUBJECTS WILL BE OFFERED EXPERIMENTAL TREATMENT WITHOUT RANDOMIZATION. PART B (ACUTE) SUBJECTS WILL BE DOUBLE-BLIND RANDOMIZED TO EXPERIMENTAL OR PLACEBO TREATMENT.
Drug: Ghrelin (OXE-103)
40ug/kg twice daily by self-injection
40ug/kg twice daily by self-injection
Symptom Management - Post Concussion Symptom Scale
The primary goal is to describe the change in severity of symptoms in sub-acute concussion with treatment with OXE-103 using the Post Concussion Symptom Scale questionnaire during the intervention period at days 1 and 15 as well as during the post-treatment period at day 44. The Post Concussion Symptom Scale questionnaire consists of 23 common concussion symptoms which are assigned a ranking of severity on a scale from 0 (no symptom) to 6 (severe symptom). This tool is used to capture both severity of concussion symptoms as well as the number of symptoms. Data will be reported with the total values of all 23 subscale symptoms (total score = sum of all subscale symptom scores)--total can range from 0 to 138 with lower scores indicating lower symptom burden and higher scores a higher symptom burden (lower score = better outcome)
Time frame: Days 1, 15, and 44
Quality of Life - QOLIBRI-OS
A secondary goal is to examine change in quality of life with treatment of sub-acute concussion using the Quality of Life after Brain Injury The QOLIBRI scores are reported on a 0-100 scale , where 0=worst possible quality of life and 100=best possible quality of life. Responses to the 'satisfaction' items (i.e. items on the Cognition, Self, Daily Life \& Autonomy, and Social Relationships scales) are on a 1-5 scale, 1= "not at all satisfied" and 5="very satisfied". Responses to the 'bothered' items (i.e. items on the Emotions and Physical Problems scales) are reverse scored to correspond with the satisfaction items, where 1="very bothered" and 5="not at all bothered". The responses on each scale are summed to give a total, and then divided by the number of responses to give a scale mean. The scale means have a maximum possible range of 1 to 5. In a similar manner the QOLIBRI Total score is calculated by summing all the responses, and then dividing by the actual number of responses.
Time frame: Days 1, 15, and 44
| Milestone | Placebo/Standard of Care | Ghrelin (OXE-103) |
|---|---|---|
| Started | 8 | 15 |
| Completed | 6 | 13 |
| Not completed | 2 | 2 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
The primary goal is to describe the change in severity of symptoms in sub-acute concussion with treatment with OXE-103 using the Post Concussion Symptom Scale questionnaire during the intervention period at days 1 and 15 as well as during the post-treatment period at day 44. The Post Concussion Symptom Scale questionnaire consists of 23 common concussion symptoms which are assigned a ranking of severity on a scale from 0 (no symptom) to 6 (severe symptom). This tool is used to capture both severity of concussion symptoms as well as the number of symptoms. Data will be reported with the total values of all 23 subscale symptoms (total score = sum of all subscale symptom scores)--total can range from 0 to 138 with lower scores indicating lower symptom burden and higher scores a higher symptom burden (lower score = better outcome)
| score on a scale | Standard of Care | Ghrelin (OXE-103) |
|---|---|---|
| Day 1 | 44 (28 to 71) | 71 (47 to 73) |
| Day 15 | 39 (28 to 68) | 51 (24 to 69) |
| Day 44 | 45 (6 to 67) | 20 (7 to 43) |
| Change Day 15-Day 1 | -1 (-14 to 4) | -21 (-30 to -6) |
| Change Day 44-Day 1 | -7 (-22 to 16) | -34 (-44 to -24) |
A secondary goal is to examine change in quality of life with treatment of sub-acute concussion using the Quality of Life after Brain Injury The QOLIBRI scores are reported on a 0-100 scale , where 0=worst possible quality of life and 100=best possible quality of life. Responses to the 'satisfaction' items (i.e. items on the Cognition, Self, Daily Life \& Autonomy, and Social Relationships scales) are on a 1-5 scale, 1= "not at all satisfied" and 5="very satisfied". Responses to the 'bothered' items (i.e. items on the Emotions and Physical Problems scales) are reverse scored to correspond with the satisfaction items, where 1="very bothered" and 5="not at all bothered". The responses on each scale are summed to give a total, and then divided by the number of responses to give a scale mean. The scale means have a maximum possible range of 1 to 5. In a similar manner the QOLIBRI Total score is calculated by summing all the responses, and then dividing by the actual number of responses.
| score on a scale | Standard of Care | Ghrelin (OXE-103) |
|---|---|---|
| Day 1 | 13 (11 to 14) | 8 (7 to 15) |
| Day 15 | 11 (7 to 17) | 17 (8 to 19) |
| Day 44 | 10 (7 to 18) | 18 (12 to 23) |
| Change Day 15-Day 1 | 1 (-4 to 6) | 2 (1 to 6) |
| Change Day 44-Day 1 | 1 (-6 to 5) | 5 (3 to 12) |
Collected over 44 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/Standard of Care | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Ghrelin (OXE-103) | 0/15 (0%) | 0/15 (0%) | 15/15 (100%) |
| Event | Placebo/Standard of Care | Ghrelin (OXE-103) |
|---|---|---|
| BruisingSkin and subcutaneous tissue disorders | 0/6 | 8/15 |
| Increased appetiteMetabolism and nutrition disorders | 0/6 | 8/15 |
| Stomach GurglingGastrointestinal disorders | 0/6 | 7/15 |
| Injection site painSkin and subcutaneous tissue disorders | 0/6 | 5/15 |
| NauseaGastrointestinal disorders | 0/6 | 4/15 |
| FatigueGeneral disorders | 0/6 | 4/15 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/6 | 3/15 |
| DiarrheaGastrointestinal disorders | 0/6 | 2/15 |
| VomitingGastrointestinal disorders | 0/6 | 2/15 |
| Hot flashVascular disorders | 0/6 | 2/15 |
| Age, Continuous(years) | Placebo/Standard of Care | Ghrelin (OXE-103) | Total |
|---|---|---|---|
| Median | 33 (30 to 43) | 42 (41 to 51) | 42 (35 to 49) |
| Sex: Female, Male(Participants) | Placebo/Standard of Care | Ghrelin (OXE-103) | Total |
|---|---|---|---|
| Female | 7 | 11 | 18 |
| Male | 1 | 4 | 5 |
| Race (NIH/OMB)(Participants) | Placebo/Standard of Care | Ghrelin (OXE-103) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 8 | 14 | 22 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(participants) | Placebo/Standard of Care | Ghrelin (OXE-103) | Total |
|---|---|---|---|
| United States | 8 | 15 | 23 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.